ReviewBlood cancer journal2026
Immune escape mechanisms and therapeutic advances in virus-associated hematological malignancies.
Review in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immunomodulatory Strategies for Managing Viral Infections in Solid Organ Transplantation: Progress and Challenges.Current microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Virus-associated hematological malignancies have become a key focus in oncology research due to their complex pathological mechanisms and unique immune escape capabilities. In recent years, research in this area has increased with a deeper understanding of the role of viruses in tumorigenesis. However, the immune escape mechanisms in virus-associated hematological malignancies remain incompletely elucidated, posing challenges for the development and optimization of treatment strategies. This review summarizes the roles of various known viruses-particularly Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), human T-cell leukemia virus type 1 (HTLV-1), Kaposi's sarcoma-associated herpesvirus (KSHV), hepatitis B virus (HBV), and hepatitis C virus (HCV) in the pathogenesis of hematological malignancies. It focuses on elucidating how tumor cells utilize multiple immune escape mechanisms to evade host immune surveillance. Simultaneously, incorporating the latest research advances, it delves into cutting-edge therapeutic approaches, including targeting viral proteins, immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, oncolytic viruses, virus-specific T-cell therapy (VST), and therapeutic vaccines. By integrating the molecular mechanisms of virus-associated hematological malignancies with clinical applications, this article aims to provide a theoretical basis and future research directions for precision therapy in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.